Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Reply to A.-S. Dieudonné et al and J.M. Rae et al.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jul 20;31(21):2755-6. No abstract available.

PMID:
24040664
2.

CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.

Rae JM, Regan M, Leyland-Jones B, Hayes DF, Dowsett M.

J Clin Oncol. 2013 Jul 20;31(21):2753-5. doi: 10.1200/JCO.2013.49.4278. Epub 2013 Jun 17. No abstract available.

PMID:
23775974
3.

Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22. No abstract available.

4.

Why should results from metastatic trials no longer matter for early-stage disease?

Dieudonné AS, Lambrechts D, Wildiers H, Neven P.

J Clin Oncol. 2013 Jul 20;31(21):2753. doi: 10.1200/JCO.2012.48.5508. Epub 2013 Jun 17. No abstract available.

PMID:
23775964
5.

CYP2D6 genotype and tamoxifen response.

Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA.

Breast Cancer Res. 2005 Jul 29;7(5):E6. No abstract available.

6.

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply.

Brauch H, Schwab M.

Br J Clin Pharmacol. 2014 Aug;78(2):433-4. doi: 10.1111/bcp.12330. No abstract available.

7.

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

Kelly CM, Pritchard KI.

J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6. No abstract available.

PMID:
22395645
8.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA.

J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31. No abstract available.

PMID:
22851270
9.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

Stanton V Jr.

J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8. doi: 10.1093/jnci/djs305. Epub 2012 Jul 31. No abstract available.

PMID:
22851267
10.

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Pharoah PD, Abraham J, Caldas C.

J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31. No abstract available.

PMID:
22851268
11.

CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.

Damkier P.

Br J Clin Pharmacol. 2014 Aug;78(2):431-2. doi: 10.1111/bcp.12329. No abstract available.

12.

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

Hayes DF, Stearns V, Rae J, Flockhart D; Consortium on Breast Cancer Pharmacogenomics.

J Natl Cancer Inst. 2008 May 7;100(9):610-3. doi: 10.1093/jnci/djn127. Epub 2008 Apr 29. No abstract available.

13.

Interpreting the CYP2D6 results from the International Tamoxifen Pharmacogenetics Consortium.

Province MA, Altman RB, Klein TE.

Clin Pharmacol Ther. 2014 Aug;96(2):144-6. doi: 10.1038/clpt.2014.100. Review. No abstract available.

14.

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response.

Wegman PP, Wingren S.

Breast Cancer Res. 2005 Mar 29;7(6):E7. No abstract available.

15.

CYP2D6 genotype and adjuvant tamoxifen.

Berry DA.

Clin Pharmacol Ther. 2014 Aug;96(2):138-40. doi: 10.1038/clpt.2014.96. No abstract available.

PMID:
25056391
16.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Gaston C, Kolesar J.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

PMID:
19194367
17.

The ethics of CYP2D6 testing for patients considering tamoxifen.

Hartman AR, Helft P.

Breast Cancer Res. 2007;9(2):103.

18.

Should CYP2D6 be genotyped when treating with tamoxifen?

Del Re M, Rofi E, Citi V, Fidilio L, Danesi R.

Pharmacogenomics. 2017 Jun;18(8):755-756. doi: 10.2217/pgs-2017-0065. Epub 2017 Jun 8.

PMID:
28593824
19.

Inherited gene affects tamoxifen's benefit in some breast cancers.

[No authors listed]

Mayo Clin Womens Healthsource. 2006 Jun;10(6):3. No abstract available.

PMID:
16675918
20.

Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.

Brauch H, Schwab M.

Br J Clin Pharmacol. 2014 Apr;77(4):695-703. doi: 10.1111/bcp.12229.

Supplemental Content

Support Center